- COVID-19
- Biosimilars
- Cataract Therapeutics
- DME
- Gene Therapy
- Workplace
- Ptosis
- Optic Relief
- Imaging
- Geographic Atrophy
- AMD
- Presbyopia
- Ocular Surface Disease
- Practice Management
- Pediatrics
- Surgery
- Therapeutics
- Optometry
- Retina
- Cataract
- Pharmacy
- IOL
- Dry Eye
- Understanding Antibiotic Resistance
- Refractive
- Cornea
- Glaucoma
- OCT
- Ocular Allergy
- Clinical Diagnosis
- Technology
OccuLogix finalizes SOLX acquisition
OccuLogix Inc. has completed its acquisition of SOLX Inc. OccuLogix acquired SOLX by way of a merger of SOLX and a wholly owned subsidiary of OccuLogix, with SOLX surviving the merger and becoming the wholly owned subsidiary of OccuLogix.
OccuLogix Inc. has completed its acquisition of SOLX Inc. OccuLogix acquired SOLX by way of a merger of SOLX and a wholly owned subsidiary of OccuLogix, with SOLX surviving the merger and becoming the wholly owned subsidiary of OccuLogix.
SOLX’s President and Chief Executive Officer (CEO) Doug Adams has joined OccuLogix as the president of the new subsidiary.
“We are very excited to welcome Doug and his entire team at SOLX to the OccuLogix family,” said OccuLogix Chairman and CEO Elias Vamvakas. “Our objective is to build a leading ophthalmic device company that is focused on age-related eye diseases.
“We are confident that the acquisition of SOLX will demonstrate our ability to identify and then acquire or partner with new technologies that leverage our expertise in sales, marketing, and regulatory along with our existing sales footprint to bring new therapies to market successfully,” added Vamvakas.
